NCT05483023 2025-10-14
18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
Clinical Trials
13 trialsNCT05419817 2023-02-27
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
University of Pittsburgh
Phase 2 Withdrawn
NCT01244438 2021-12-13
Study of FP-1039 in Subjects With Endometrial Cancers
Five Prime Therapeutics, Inc.
Phase 2 Withdrawn
NCT02127151 2021-08-06
PANDA
University College, London
Phase 2 Withdrawn
NCT04197219 2020-11-05
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT03836157 2019-06-27
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
University of Oklahoma
Phase 2 Withdrawn
NCT00003821 2018-09-18
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer
Sanofi
Phase 2 Withdrawn
NCT03005015 2016-12-29
Lenvatinib in Second Line Endometrial Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT02042495 2016-08-30
Endometrial Cancer Biomarker Changes Following Exposure to Metformin
Jewish General Hospital
Phase 2 Withdrawn
NCT02095847 2015-04-08
High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01943058 2014-09-10
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
University of Southern California
Phase 2 Withdrawn
NCT01550380 2014-07-29
BKM120
University of Utah
Phase 2 Withdrawn
NCT01290406 2012-06-21
BEZ235 Trial in Patients With Advanced Endometrial Carcinoma
Novartis
Phase 2 Withdrawn